Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential
- 19 April 2007
- journal article
- review article
- Published by Springer Nature in Amino Acids
- Vol. 33 (2) , 213-223
- https://doi.org/10.1007/s00726-007-0531-2
Abstract
The activity of ornithine decarboxylase (ODC1), the first enzyme in polyamine biosynthesis, is induced during carcinogenesis by a variety of oncogenic stimuli. Intracellular levels of ODC and the polyamines are tightly controlled during normal cell growth, and regulation occurs at the levels of transcription, translation and protein degradation. Several known proto-oncogenic pathways appear to control ODC transcription and translation, and dysregulation of pathways downstream of ras and myc result in the constitutive elevation of ODC activity that occurs with oncogenesis. Inhibition of ODC activity reverts the transformation of cells in vitro and reduces tumor growth in several animal models, suggesting high levels of ODC are necessary for the maintenance of the transformed phenotype. The ODC irreversible inactivator DFMO has proven to be not only a valuable tool in the study of ODC in cancer, but also shows promise as a chemopreventive and chemotherapeutic agent in certain types of malignancies.Keywords
This publication has 41 references indexed in Scilit:
- Role of polyamines in arginine‐dependent colon carcinogenesis in ApcMin/+ miceMolecular Carcinogenesis, 2006
- Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cellsOncogene, 2005
- Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formationCancer Cell, 2005
- Effects of Polyamine Synthesis Inhibitors on Primary Tumor Features and Metastatic Capacity of Human Breast Cancer CellsClinical & Experimental Metastasis, 2005
- Tissue-based Assay for Ornithine Decarboxylase to Identify Patients Likely to Respond to DifluoromethylornithineJournal of Histochemistry & Cytochemistry, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Difluoromethylornithine and leukocyte interferon: A phase I study in cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1986
- Effect of alpha-difluoromethylornithine in lung metastases before and after surgery of primary adenocarcinoma tumors in miceBiology of the Cell, 1985
- Treatment of metastatic lewis lung carcinoma with dl-α-difluoromethylornithineEuropean Journal of Cancer and Clinical Oncology, 1983
- Inhibition of EMT6 tumor growth by interference with polyamine biosynthesis ; Effects of α-difluoromethyl- ornithine, an irreversible inhibitor or ornithine decarboxylaseLife Sciences, 1980